Analytical Overview of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD)


ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) currently has a “Sell” signals on Composite indicators by TrendSpotter. While the Short-Term Technical Indicators for the stock on 7-Day Average Directional Indicator shows “Buy” signal. 10 – 8 Day Moving Average Hilo Channel shows “Buy” signal. While 20-Day Moving Average VS Current Price shows “Buy” Signal.

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) gained 5.59 Percent and closed its previous trading session at $17.76. The stock traded with the average Volume of 3.24 Million at the end of last session.

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) has the Market Capitalization of 2.22 Billion. The Stock has its 52-week High of $41.20 and 52-Week Low of $14.51 and it touched its 52-week high on 10/05/17 and 52-Week Low on 04/25/18


The company reported its last earnings Actual EPS of $-0.44/share. While, the analyst predicted that the company could provide an EPS of $-0.55/share. Hence the difference between Predicted EPS and Actual EPS reported is $0.11/share which shows an Earnings Surprise of 20 Percent.

Sell side analysts plays vital role in buying and selling a stock where 1 analysts rated ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) as Buy, 0 analysts given Outperform signal, 0 reported Hold, and 0 analysts rated the stock as Sell.

The stock’s current distance from 20-Day Simple Moving Average (SMA20) is 9.28% where SMA50 and SMA200 are 3.37% and -31.05% respectively.

The company shows its Return on Assets (ROA) value of -63.7%. The Return on Equity (ROE) value stands at -71.5%. While it’s Return on Investment (ROI) value is -67%.

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) currently has a Weekly Volatility of 7.88% percent while its Monthly Volatility is at 7.21% percent. While talking about Performance of the Stock, ACADIA Pharmaceuticals Inc. currently has a Weekly performance of 6.73%, monthly performance percentage is 0.51 percent, Quarterly performance is -7.93 percent, 6 months performance shows a percent value of -37.97% and Yearly Performance is -36.46 percent.

Company Profile:

Acadia Pharmaceuticals is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule drugs for the treatment of central nervous system disorders. Their three clinical programs are ACP-103 for treatment-induced dysfunction in Parkinson’s disease, and ACP-104 and ACP-103, both for the treatment of schizophrenia.